patent ductus arteriosus
Conditions
Interventions
Standard group:First day 10mg/kg,then 5 mg/kg for last two days
High dose group:10mg/kg per day,for three days
Sponsors
Children’s Hospital of Fudan University
Eligibility
Sex/Gender
All
Age
No minimum to 1 Years
Inclusion criteria
Inclusion criteria: 1. equal and less than 29 weeks' gestational age; 2. Diagnosis of PDA, according to echocardiography; 3. Written informed consent obtained from his/her parents; 4. Male and female, age of 2 to 7 days after birth.
Exclusion criteria
Exclusion criteria: 1. congenital anomalies; 2. severe infection; 3. intraventricular hemorrhage; 4. urine output below 1 ml/kg/h during the preceding 8 hours; 5. hyperbilirubinemia necessitating exchange transfusion; 6. serum creatinine concentration =1.6 mg/dL (140 µmol/L); 7. platelet count = 60,000 per cubic millimeter; 8. a tendency to bleed, as revealed by hematuria, blood in the endotracheal aspirate, gastric aspirate, or stools, and oozing from puncture sites; 9. Infant included in other clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| patent ductus arteriosus closure rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Bleeding; | — |
Countries
China
Contacts
Public ContactZhiping Li
Children's Hospital of Fudan University
Outcome results
None listed